Literature DB >> 8203907

Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450.

T K Chang1, F J Gonzalez, D J Waxman.   

Abstract

A variety of chemicals, including triacetyloleandomycin (TAO), alpha-naphthoflavone (ANF), and diethyldithiocarbamate (DDC), are widely used as inhibitory probes for select individual human cytochrome P450 (CYP) enzymes, despite the fact that the selectivity of these inhibitors has not been rigorously evaluated. In the present study we take advantage of recent advances in cDNA-directed human P450 expression to evaluate directly the P450 form selectivity of TAO, ANF, and DDC, using a panel of 10 individual cDNA-expressed human P450s. Under experimental conditions known to yield maximal TAO complexation with P450 hemoproteins, TAO (20 microM) inhibited the catalytic activity of expressed CYPs 3A3, 3A4, and 3A5, whereas it did not affect CYPs 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, or 2E1 activity. ANF inhibited not only CYPs 1A1 and 1A2 (IC50 = 0.4-0.5 microM), but it was also similarly effective against CYPs 2C8 and 2C9. Increasing the concentration of ANF to 10 microM led to inhibition of CYP2A6 and CYP2B6. Although a previous study suggested that DDC is a selective inhibitor of CYP2E1, the present investigation shows that at concentrations required to inhibit CYP2E1 (IC50 approximately 125 microM when preincubated with NADPH), DDC also inhibited CYPs 1A1, 1A2, 2A6, 2B6, 2C8, 3A3, and 3A4. Decreasing the concentration of DDC to 10 microM, however, led to inhibition of CYP2A6 (65% inhibition) and CYP2B6 (50% inhibition), but none of the other P450s examined, including CYP2E1. Overall, these results establish that (a) TAO is a selective inhibitor of the human CYP3A subfamily; (b) ANF potently inhibits CYP2C8 and CYP2C9, in addition to CYPs 1A1 and 1A2; and (c) DDC cannot be employed as a diagnostic inhibitory probe for CYP2E1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8203907     DOI: 10.1006/abbi.1994.1259

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  23 in total

Review 1.  Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

Authors:  J F Westphal
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

2.  Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes.

Authors:  E S Guns; P L Bullock; M L Reimer; R Dixon; M Bally; L D Mayer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

3.  The effects of CYP1A inhibition on alkyl-phenanthrene metabolism and embryotoxicity in marine medaka (Oryzias melastigma).

Authors:  Jingli Mu; Fei Jin; Juying Wang; Ying Wang; Yi Cong
Journal:  Environ Sci Pollut Res Int       Date:  2016-02-29       Impact factor: 4.223

4.  Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism.

Authors:  S Gates; J O Miners
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

5.  Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole.

Authors:  C B Trapnell; C Jamis-Dow; R W Klecker; J M Collins
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  The xenobiotic inhibitor profile of cytochrome P4502C8.

Authors:  C E Ong; S Coulter; D J Birkett; C R Bhasker; J O Miners
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

7.  Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.

Authors:  D J Foster; A A Somogyi; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

8.  Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.

Authors:  V A Eagling; J F Tjia; D J Back
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

Review 9.  Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology.

Authors:  L L von Moltke; D J Greenblatt; J Schmider; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

10.  Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.

Authors:  Rajaa A Mirghani; Orjan Ericsson; Gunnel Tybring; Lars L Gustafsson; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2003-03-11       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.